Cytokinetics director Parshall sells 5,000 shares

Available on EDGAR 11/12/2026 - 04:42 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:41 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cytokinetics Inc. (CYTK) director B. Lynne Parshall reported selling 5,000 shares of common stock on November 9, 2026, in two transactions under a Rule 10b5-1 plan. The first covered 2,445 shares at a weighted-average price of $54.17 per share (range $53.72–$54.69); the second covered 2,555 shares at $55.26 per share (range $54.78–$55.71).

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 2 txns

Insider PARSHALL B LYNNE

Role Director

Sold 5,000 shs ($274K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,445	$54.17	$132K
Sale	Common Stock F2	2,555	$55.26	$141K

Holdings After Transaction: Common Stock — 5,784 shares (Direct)

Footnotes (2)

1. F1. The reported transaction involves sale transactions from $53.72 to $54.69 per share. The weighted average price per share was $54.17. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price
2. F2. The reported transaction involves sale transactions from $54.78 to $55.71 per share. The weighted average price per share was $55.26. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price

Key Figures

Shares sold: 5,000 shares Shares sold: 2,445 shares Weighted-average sale price: $54.17 per share +2 more

5 metrics

Shares sold 5,000 shares Across two transactions on November 9, 2026.

Shares sold 2,445 shares Transaction on November 9, 2026; price range $53.72–$54.69 per share.

Weighted-average sale price $54.17 per share For the 2,445-share transaction on November 9, 2026.

Shares sold 2,555 shares Transaction on November 9, 2026; price range $54.78–$55.71 per share.

Weighted-average sale price $55.26 per share For the 2,555-share transaction on November 9, 2026.

Key Terms

Rule 10b5-1 plan, weighted average price per share

2 terms

Rule 10b5-1 plan regulatory

"The reported sales were under a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price per share financial

"The weighted average price per share was $54.17"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did CYTK director B. Lynne Parshall sell?

B. Lynne Parshall reported selling 5,000 shares of Cytokinetics Inc. common stock on November 9, 2026. The two sales were made under a Rule 10b5-1 plan: 2,445 shares at a weighted-average $54.17 per share and 2,555 shares at $55.26 per share. The respective transaction price ranges were $53.72–$54.69 and $54.78–$55.71 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/09/2026		S		2,445	D	$54.17(1)	8,339	D
Common Stock	11/09/2026		S		2,555	D	$55.26(2)	5,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involves sale transactions from $53.72 to $54.69 per share. The weighted average price per share was $54.17. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price

2. The reported transaction involves sale transactions from $54.78 to $55.71 per share. The weighted average price per share was $55.26. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price

	/s/ John O. Faurescu, attorney-in-fact for Ms. Parshall	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)